Xiaohui Yi

Xiaohui Yi

Auto-generated profile, based on publicly available information

Xiaohui Yi

Semiconductor Photonics Research Center OSED Department of Physics Jiujiang Research Institute Xiamen University Xiamen 361005 China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2019 in Advanced Energy Materials
Verified
Journal Article
Closed access
PDF file
XYXiaohui Yi
Xiaohui Yi
ZZZhiming Zhang
Zhiming Zhang
ACAiling Chang
Ailing Chang
YMYichen Mao
Yichen Mao
YLYigang Luan
Yigang Luan
JWJizheng Wang
Jizheng Wang

16 August 2018 in Materials Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
XYXiaohui Yi
Xiaohui Yi
YWYisen Wang
Yisen Wang
NCNingli Chen
Ningli Chen
ZHZhiwei Huang
Zhiwei Huang
ZRZhenwei Ren
Zhenwei Ren
JWJizheng Wang
Jizheng Wang
We designed and fabricated a CH3NH3PbI3/TiO2/Si hybrid photodetector, which shows a high on/off ratio, high detectivity and broad photoresponse.

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CBCarlos Roberto Becerra
Carlos Roberto Becerra
GMGulam Abbas Manji
Gulam Abbas Manji
DKDae Won Kim
Dae Won Kim
OGOlivia Gardner
Olivia Gardner
AMAditya Malankar
Aditya Malankar
PWPaul Woodard
Paul Woodard
2536 Background: Cell-surface protein PSCA is upregulated in many solid tumors and correlates with disease stage. BPX-601, an autologous T-cell product expressing a PSCA-CD3ζ CAR and a rimiducid (Rim)-inducible MyD88/CD40 co-activation switch to augment T-cell proliferation and persistence, is designed to have enhanced efficacy in solid tumors vs traditional CARs. This ongoing first-in-human study assesses safety, biologic, and clinical activity of BPX-601+Rim in PSCA+ cancers. Updated results, including those from patients (pts) who underwent LD with Flu/Cy, are presented. Methods: BP-012 is a 2-part, open-label trial. Part 1 is a 3+3 dose escalation of BPX-601 (1.25–5.0x106 cells/kg; Day [D] 0) given prior to a single, fixed Rim dose (0.4 mg/kg; D7) in pts with previously treated PSCA+ metastatic pancreatic, gastric, or prostate cancers with measurable disease. Results: As of Jan-22-2019, 15 pts have received BPX-601±Rim. Two pts at the highest cell dose received Flu/Cy for LD on D−5 to D−3 before BPX-601; LD after Flu/Cy was 96.6% and 84.3%. Thirteen pts received Cy alone on D−3; in these pts, LD ranged from 0–68.6%. Rapid cell expansion by D4 was observed in all pts with peak vector copy number 8.3-fold higher with Flu/Cy (n = 2) vs Cy LD (n = 13). Serum IP-10, IL-6 and TNFα increased > 2-fold from baseline in ≥1 pt in all Rim cohorts, with 3- to 20-fold Rim-dependent cell expansion in 6 pts. No CRS or DLTs were reported. After Rim, one Flu/Cy pt experienced a serious Grade 2 AE (encephalopathy) related to BPX-601+Rim that resolved with IV steroids; despite time-matched nonserious Grade 1 pyrexia, the pt had no other CRS symptoms. After BPX-601+Rim and ≥1 scan, best responses were 8 SD and 3 PD (1 non-evaluable). With a median follow-up of 9.8 wks, time to next treatment (tx) after BPX-601 ranged from 2.7–22.1 wks (n = 8) and ongoing tx-free intervals range from 9.1–30.1 wks (n = 4). Conclusions: BPX-601+Rim was well-tolerated with manageable safety and early evidence of enhanced CAR T-cell expansion and prolonged persistence after Flu/Cy vs Cy. Additional pts will undergo Flu/Cy LD prior to BPX-601 with single- and repeat-dose Rim. Clinical trial information: NCT02744287.

2 September 2020 in Small Methods
Verified
Journal Article
Closed access
PDF file
XYXiaohui Yi
Xiaohui Yi
YMYichen Mao
Yichen Mao
LZLu Zhang
Lu Zhang
JZJing Zhuang
Jing Zhuang
YZYanyan Zhang
Yanyan Zhang
CLCheng Li
Cheng Li

10 February 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LCLimo Chen
Limo Chen
YLYanli Li
Yanli Li
XYXiaohui Yi
Xiaohui Yi
DGDon L. Gibbons
Don L. Gibbons
144 Background: The combination of anti-PD-1 and anti-CTLA-4 is a promising strategy that is being clinically explored to treat a variety of cancer types. Some patients display primary resistance to this combination treatment, while others relapse after treatment. Although some cancer patients have long-term durable responses to the combination therapy of anti-PD-1 and anti-CTLA-4, physicians have been looking for biomarkers that predict response. Methods: Using multiple immunocompetent syngeneic and K-rasLA1/+p53R172H?g/+ spontaneous animal models of lung cancer, we have explored the mechanisms of resistance to anti-PD-1/CTLA-4 combination therapy by evaluating the molecular and cellular immune profiles of the tumor microenvironment. Antibody-mediated cell depletion assays were also conducted to validate the mechanisms. Lastly, to determine the applicability to patients, we analyzed 791 lung cancer patients’ specimens with immunohistochemistry staining and mined many immune markers in multiple large independent patient databases (~1900 tumors). Results: We observed that tumor bearing mice treated with combined PD-1 and CTLA-4 blocking antibodies developed resistance through the up-regulation of CD38, and that targeting CD38 abolished the resistance in a manner dependent on B7-costimulation. Additionally, combined PD-1 and CTLA-4 blockade eradicates CD38-deficient tumors in mice. Further study revealed that control of tumors by triple blockade of CD38, PD-1, and CTLA-4 depended on improved functionality of CD4+/CD8+ TILs, which were reactivated by enriched CD103+ dendritic cells in the tumor microenvironment. Pathologic analysis revealed positive immunohistochemical staining for CD38 on tumor cells in 15-23% of cases and bioinformatic analyses revealed a strong correlation between CD38 expression and an immune inflammatory signature. Conclusions: Targeting CD38 improves the efficacy of anti-PD-1/CTLA-4 combination therapy in lung cancer. CD38 on tumor cells could potentially serve as a novel biomarker of resistance for immune checkpoint inhibition.

3 April 2023
Verified
Other
Open access
LCLimo Chen
Limo Chen
LDLixia Diao
Lixia Diao
YYYongbin Yang
Yongbin Yang
XYXiaohui Yi
Xiaohui Yi
BRB. Leticia Rodriguez
B. Leticia Rodriguez
DGDon L. Gibbons
Don L. Gibbons